FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 528 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR A New Online Tool Predicts RFS and OS Probabilities in Patients... February 7, 2024 Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer March 24, 2021 Marine Runs Five Marathons in Five Days to Help Fund Sister’s... April 20, 2021 Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... November 30, 2021 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ Cancer Patient’s Appetite Increases And His Blood Pressure Lowers After A... How does processed and red meat cause cancer and how much... Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated...
